Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Interim safety results from the phase 2 ABOUND.PS2 study evaluating nab-paclitaxel (nab-P) + carboplatin (C) followed by nab-P monotherapy in patients (pts) with NSCLC and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2

Date

08 Oct 2016

Session

Poster Display

Presenters

Ajeet Gajra

Citation

Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383

Authors

A. Gajra1, H. Ali2, K.I. Amiri3, N. Abdel Karim4, M.R. Matrana5, D. Mulford6, T.J. Ong3, A. Sanford3, E. Santos7, M. Socinski8, D.R. Spigel9, R.C. Lilenbaum10

Author affiliations

  • 1 Hematology/oncology:, Upstate Medical University, State University of New York, 13210 - Syracuse/US
  • 2 Hematology, Henry Ford Hospital, Detroit/US
  • 3 Medical Affairs, Celgene Corporation, Summit/US
  • 4 Oncology, University of Cincinnati, Cincinnati/US
  • 5 Oncology, Ochsner Medical Center, New Orleans/US
  • 6 Hematology/oncology, University of Rochester Medical Center, Rochester/US
  • 7 Medicine, Eugene M and Christine E Lynn Cancer Center, 33486 - Boca Raton/US
  • 8 Medical Oncology, University of Pittsburgh UPMC Cancer Pavilion, Pittsburgh/US
  • 9 Oncology, Sarah Cannon Research Institute, 37203 - Nashville/US
  • 10 Oncology, Yale Cancer Center, New Haven/US
More

Resources

Abstract 1595

Background

Pts with poor PS can benefit from combination chemotherapy; however, they may be at greater risk for toxicity vs pts with good PS. Here, we report interim safety results in pts with advanced NSCLC and an ECOG PS 2 treated with nab-P/C followed by nab-P monotherapy.

Methods

Pts with stage IIIB/IV NSCLC, no prior anti-cancer therapy for metastatic disease, and an ECOG PS 2 received nab-P 100 mg/m2 d 1 and 8 + C area under the curve 5 d 1 (21-d cycles) for 4 cycles. Starting at cycle 5, pts without progression could continue nab-P 100 mg/m2 monotherapy d 1 and 8 (21-d cycles) until progression/unacceptable toxicity. The primary endpoint is percentage of pts discontinuing treatment during the first 4 cycles due to treatment-emergent adverse events (TEAEs).

Results

As of April 4, 2016, 31 pts were treated. Median age was 71 y, 61% were male, 61% had nonsquamous NSCLC, and 39% had squamous NSCLC. Overall, 14/31 pts remained on therapy at the time of this analysis; 13 pts discontinued in the first 4 cycles and 4 pts from cycle 5 onwards (5 due to AEs, 5 due to progression, 4 due to pt decision, 2 due to symptomatic deterioration, and 1 due to other reasons). In all treated pts, the median percentage of per-protocol dose of nab-P was 85%. Dose adjustments included at least 1 nab-P dose not administered, dose delay, or dose reduction (13, 12, and 7 pts, respectively). Overall, the median dose intensity for nab-P was 56.58 mg/m2/week (expected, 66.7 mg/m2/week). Serious TEAEs occurred in 48% of pts; the incidence of each individual serious TEAE reported was 

Conclusions

Pts with PS 2 are at risk for greater toxicity with combination therapy, but these interim results indicate that a tailored nab-P/C regimen is feasible with a manageable safety profile, and may be an appropriate treatment option regardless of histology. NCT02289456

Clinical trial identification

NCT02289456

Legal entity responsible for the study

N/A

Funding

Celgene Corporation

Disclosure

A. Gajra: Consultant to Celgene Corporation. K.I. Amiri, T.J. Ong, A. Sanford: Employee of Celgene and owns stock. N. Abdel Karim: Advisory for Pfizer, Prometheus, Novartis and Bayer. E. Santos: Member of the following Speakers' Bureaus: Celgene, Pfizer, Amgen, Genetech, Lily, BI, Millenium. M. Socinski: Honorarium and member of Celgene's Speakers Bureau. D.R. Spigel: Consultant, member of speakers' bureau, received research funding and travel expenses from Celgene. R.C. Lilenbaum: Consulting or Advisory Role: Genentech/Roche, Boehringer Ingelheim, Celgene Travel, Accommodations, Expenses: Roche. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings